LENZ Therapeutics Inc.’s recent filing unveils that its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $15.0 million on Mar 21 ’24. In the deal valued at $15.03 per share,998,009 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 3,319,339 shares worth roughly $52.68 million.
William Blair initiated its LENZ Therapeutics Inc. [LENZ] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in mid April with a ‘”an Outperform”‘ rating. Citigroup began covering LENZ with “Buy” recommendation on April 10, 2024. Piper Sandler started covering the stock on March 27, 2024. It rated LENZ as “an Overweight”.
Price Performance Review of LENZ
On Tuesday, LENZ Therapeutics Inc. [NASDAQ:LENZ] saw its stock fall -3.82% to $15.87. Over the last five days, the stock has lost -0.31%. LENZ Therapeutics Inc. shares have risen nearly 22.91% since the year began. Nevertheless, the stocks have risen 0.95% over the past one year. While a 52-week high of $24.59 was reached on 03/11/24, a 52-week low of $9.91 was recorded on 04/26/24. SMA at 50 days reached $20.53, while 200 days put it at $18.24.
Levels Of Support And Resistance For LENZ Stock
The 24-hour chart illustrates a support level at 15.34, which if violated will result in even more drops to 14.80. On the upside, there is a resistance level at 16.56. A further resistance level may holdings at 17.25. The Relative Strength Index (RSI) on the 14-day chart is 39.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.32%. Stochastics %K at 13.96% indicates the stock is a buying.
